Immunotherapy for stage 4 prostate cancer is revolutionizing the way advanced disease is being treated, offering hope for patients worldwide. Unlike conventional treatment methods such as surgery and ...

Immunotherapy is simply a term that describes utilizing your own body's immune system to fight cancer cells. It's often been called a prostate cancer vaccine. After discussion with their doctor, men ...

Black men with advanced prostate cancer have a greater chance of survival after immunotherapy treatment, at least in part, because of ancestral gene variants in immune responses. That connection is ...

In a recent interview with CURE, Dr. Kai Tsao broke down current treatment advancements for patients with prostate cancer.

Delivery of a new nanoparticle-based immunotherapy to perivascular tumour-associated macrophages (TAMs) in androgen deprivation therapy (ADT)-treated prostate tumours may increase antitumour immunity ...

New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors. In a recent study, it was found ...

Please provide your email address to receive an email when new articles are posted on . The addition of a pre-ketone supplement to an immunotherapy regimen demonstrated efficacy for treating prostate ...

Researchers at the University of Arizona Health Sciences have uncovered a promising new approach for treating prostate cancer through a combination of immunotherapy and a targeted treatment strategy.

New research has shown that immunotherapy can be effective in treating prostate cancer in men who are selected based on the genetic characteristics of their tumors. In a recent study conducted at ...

NEW YORK, NY--Immunotherapy has been disappointing as a prostate cancer treatment, but a new Columbia study suggests that the powerful treatments have potential when the disease starts to spread. The ...

In this exclusive MedPage Today video, Tanya Dorff, MD, of City of Hope in Duarte, California, discusses two prostate cancer immunotherapy studies presented at the recent American Society of Clinical ...

The immunotherapy CAN-2409 added to standard EBRT without ADT is a potential paradigm-shifting therapy for localized intermediate- to high-risk prostate cancer. CAN-2409, an adenoviral vector, plus ...